Effects of long-term feeding with 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine (PhIP) in C57BL/ByA and E μ- pim-1 mice

The heterocyclic amine PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine, has been shown to be carcinogenic in rats producing colon and mammary carcinomas. There is, so far, only a single long-term study report on PhIP carcinogenicity in mice. However, this study focuses on the lymphoma inducti...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 1998-01, Vol.122 (1), p.215-220
Main Authors: Kristiansen, Eva, Mortensen, Alicja, Kryspin Sørensen, Ilona
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
C57BL/6ByA mice
Carcinogenesis, carcinogens and anticarcinogens
Carcinogens - toxicity
Chemical agents
E μ- pim-1 mice
Female
Imidazoles - toxicity
Long-term feeding study
Lymphoma - chemically induced
Male
Medical sciences
Mice
Mice, Inbred C57BL
PhIP
Species Specificity
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The heterocyclic amine PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine, has been shown to be carcinogenic in rats producing colon and mammary carcinomas. There is, so far, only a single long-term study report on PhIP carcinogenicity in mice. However, this study focuses on the lymphoma induction only. Whether PhIP induces tumors in other organs in mice after long-term exposure is yet to be established. To contribute to the knowledge about the long-term effects of PhIP feeding the remaining animals from a 7 months feeding study (0.03% PhIP) were put on standard diet and followed up to 18 months. The results confirmed that PhIP is a potent mouse lymphomagen. In addition, treatment with 0.03% PhIP in the diet for the first 7 months of a life-time study (18 months) gave rise to very few and sporadic tumors in other tissues, indicating weak, if any, carcinogenicity of PhIP to organs other than the lymphatic system under the present study design.
ISSN:0304-3835
1872-7980
DOI:10.1016/S0304-3835(97)00388-1